Free Trial
NASDAQ:TLSI

TriSalus Life Sciences (TLSI) Stock Price, News & Analysis

TriSalus Life Sciences logo
$4.53 +0.10 (+2.26%)
(As of 11/22/2024 ET)

About TriSalus Life Sciences Stock (NASDAQ:TLSI)

Key Stats

Today's Range
$4.33
$4.65
50-Day Range
$3.67
$4.67
52-Week Range
$3.33
$10.42
Volume
38,153 shs
Average Volume
38,411 shs
Market Capitalization
$138.12 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$12.08
Consensus Rating
Buy

Company Overview

TriSalus Life Sciences, Inc., a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer. It also develops nelitolimod, an investigational immunotherapeutic in Phase 1 clinical trial for the treatment of uveal melanoma with liver metastases, hepatocellular carcinoma, intrahepatic cholangiocarcinoma, and locally advanced pancreatic ductal adenocarcinoma. The company serves interventional radiologists, IR technicians, medical oncologists, nursing support, value analysis committee staff, and patients through its sales representatives and sales managers. TriSalus Life Sciences, Inc. was founded in 2009 and is headquartered in Westminster, Colorado.

TriSalus Life Sciences Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
88th Percentile Overall Score

TLSI MarketRank™: 

TriSalus Life Sciences scored higher than 88% of companies evaluated by MarketBeat, and ranked 144th out of 953 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    TriSalus Life Sciences has received a consensus rating of Buy. The company's average rating score is 3.25, and is based on 6 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    TriSalus Life Sciences has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about TriSalus Life Sciences' stock forecast and price target.
  • Earnings Growth

    Earnings for TriSalus Life Sciences are expected to grow in the coming year, from ($1.55) to ($0.61) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of TriSalus Life Sciences is -1.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of TriSalus Life Sciences is -1.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Percentage of Shares Shorted

    1.26% of the float of TriSalus Life Sciences has been sold short.
  • Short Interest Ratio / Days to Cover

    TriSalus Life Sciences has a short interest ratio ("days to cover") of 1.3, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in TriSalus Life Sciences has recently decreased by 5.96%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    TriSalus Life Sciences does not currently pay a dividend.

  • Dividend Growth

    TriSalus Life Sciences does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    1.26% of the float of TriSalus Life Sciences has been sold short.
  • Short Interest Ratio / Days to Cover

    TriSalus Life Sciences has a short interest ratio ("days to cover") of 1.3, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in TriSalus Life Sciences has recently decreased by 5.96%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    TriSalus Life Sciences has a news sentiment score of 0.31. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.49 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 6 news articles for TriSalus Life Sciences this week, compared to 1 article on an average week.
  • Search Interest

    4 people have searched for TLSI on MarketBeat in the last 30 days.
  • MarketBeat Follows

    3 people have added TriSalus Life Sciences to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, TriSalus Life Sciences insiders have bought 144,780.00% more of their company's stock than they have sold. Specifically, they have bought $72,440.00 in company stock and sold $50.00 in company stock.

  • Percentage Held by Insiders

    32.80% of the stock of TriSalus Life Sciences is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 2.58% of the stock of TriSalus Life Sciences is held by institutions.

  • Read more about TriSalus Life Sciences' insider trading history.
Receive TLSI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for TriSalus Life Sciences and its competitors with MarketBeat's FREE daily newsletter.

TLSI Stock News Headlines

Comparing TriSalus Life Sciences (TLSI) & Its Competitors
Trump won. Buy this coin now.
Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will go to $150,000 — or more. But there’s one coin he thinks could go even higher.
TriSalus Life Sciences price target lowered to $11 from $12 at Canaccord
Roth MKM Reaffirms Their Buy Rating on TriSalus Life Sciences (TLSI)
TriSalus Life Sciences sees FY25 revenue growth ‘more than 50%’
See More Headlines

TLSI Stock Analysis - Frequently Asked Questions

TriSalus Life Sciences' stock was trading at $8.45 at the start of the year. Since then, TLSI shares have decreased by 46.4% and is now trading at $4.53.
View the best growth stocks for 2024 here
.

Top institutional shareholders of TriSalus Life Sciences include Geode Capital Management LLC (0.66%), MSD Partners L.P. (0.13%), Vestcor Inc (0.08%) and Virtu Financial LLC (0.07%). Insiders that own company stock include Mary T Szela, George Kelly Martin and Mats Wahlstrom.
View institutional ownership trends
.

Shares of TLSI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that TriSalus Life Sciences investors own include AutoZone (AZO), Intel (INTC), Meta Platforms (META), Merck & Co., Inc. (MRK), TJX Companies (TJX), Abacus Health Products (ABAHF) and Airbnb (ABNB).

Company Calendar

Today
11/23/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
Medical Equipment
Current Symbol
NASDAQ:TLSI
Previous Symbol
NASDAQ:TLSI
Fax
N/A
Employees
106
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$12.08
High Stock Price Target
$16.00
Low Stock Price Target
$10.00
Potential Upside/Downside
+166.7%
Consensus Rating
Buy
Rating Score (0-4)
3.25
Research Coverage
8 Analysts

Profitability

Net Income
$-59,040,000.00
Net Margins
-206.24%
Pretax Margin
-205.69%

Debt

Sales & Book Value

Annual Sales
$18.51 million
Book Value
($0.67) per share

Miscellaneous

Free Float
20,490,000
Market Cap
$138.12 million
Optionable
Not Optionable
Beta
0.49
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

This page (NASDAQ:TLSI) was last updated on 11/23/2024 by MarketBeat.com Staff
From Our Partners